Recent advances in vaccine adjuvants

Pharmaceutical Research

Volumn 19, Issue 6, 2002, Pages 715-728

  Singh, Manmohan ^a   O'Hagan, Derek T ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Emulsions; Immunostimulators; Microparticles; Vaccine adjuvants; Vaccine delivery systems

Indexed keywords

ALUMINUM HYDROXIDE; CHITOSAN; CHOLERA TOXIN; CYTOKINE; ENTEROTOXIN; FREUND ADJUVANT; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 2; LIPOSOME; PHOSPHORYL LIPID A; PLASMID DNA; POLOXAMER; POLYMER; SAPONIN; VACCINE;

ANTIGEN PRESENTING CELL; DRUG DELIVERY SYSTEM; EMULSION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOSTIMULATION; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; VACCINATION;

EID: 0036296053     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016104910582     Document Type: Short Survey

References (191)

1. DNA vaccines - Designer vaccines for the 21st century
2. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine
3. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients
4. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara
5. Development of a preventive vaccine for Ebola virus infection in primates
6. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
7. Sur la toxine et surranatoxine diphtheriques
8. A compendium of vaccine adjuvants and excipients
9. Aluminum compounds as vaccine adjuvants
10. Rational approaches to reduce adverse reactions in man to vaccines containing tetanus and diphtheria toxoids
11. In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid
12. The common vaccine adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via an interleukin-4-dependent mechanism
13. Detoxification of endotoxin by aluminum hydroxide adjuvant
14. Adjuvants for the future
15. Antigen localisation regulates immune responses in a dose- and time-dependent fashion: A geographical view of immune reactivity
16. A theory of self-nonself discrimination
17. Approaching the asymptote? Evolution and revolution in immunology
18. Innate immunity: The virtues of a nonclonal system of recognition
19. Tolerance, danger, and the extended family
20. An innate sense of danger
21. Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses
22. Seeking wisdom in innate immunity
23. The instructive role of innate immunity in the acquired immune response
24. Adjuvant-guided type-1 and type-2 immunity: Infectious/noninfectious dichotomy defines the class of response
25. Bacterial cell wall products as adjuvants: Early interferon gamma as a marker for adjuvants that enhance protective immunity
26. Monophosphoryl lipid A as an adjuvant: Past experiences and new directions
27. MPLr immunostimulant: Adjuvant formulations
28. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system
29. A Th1-inducing adjuvant, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines
30. 3-O-Desacyl monophosphoryl lipid A derivatives: Synthesis and immunostimulant activities
31. A novel class of endotoxin receptor agonists with simplified structure, toll-like receptor 4-dependent immunostimulatory action, and adjuvant activity
32. Monophosphoryl lipid A enhances both humoral and cell-mediated immune responses to DNA vaccination against human immunodeficiency virus type 1
33. Adjuvant activity of monophosphoryl lipid A for nasal and oral immunization with soluble or liposome-associated antigen
34. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA
35. Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity
36. CpG motifs in bacterial DNA trigger direct B-cell activation
37. CpG islands as gene markers in the vertebrate nucleus
38. A Toll-like receptor recognizes bacterial DNA
39. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells
40. CpG motifs as immune adjuvants
41. Cationic microparticles are an effective delivery system for immune stimulatory CpG DNA
42. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice
43. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo
44. Saponins as vaccine adjuvants
45. Action of saponins on biologic membranes
46. QS-21: A water-soluble triterpene glycoside adjuvant
47. QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans
48. Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21
49. Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes
50. Cytokines as immunologic adjuvants
51. Use of cellular and cytokine adjuvants in the immunotherapy of cancer
52. An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity
53. Freund's adjuvants
54. MF59: Design and evaluation of a safe and potent adjuvant for human vaccines
55. The adjuvant MF59 increases the immunogenicity and protective efficacy of subunit influenza vaccine in mice
56. MF59 adjuvant enhances the immunogenicity of influenza vaccine in both young and old mice
57. Recent advances in vaccine adjuvants: The development of MF59 emulsion and polymeric microparticles
58. MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates
59. Influenza vaccines: Antibody responses to split virus and MF59-adjuvanted subunit virus in an adult population
60. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly
61. Trade systems in less-developed countries
62. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant
63. MF59 adjuvant enhances antibody responses of infant baboons immunized with Haemophilus influenzae type b and Neisseria meningitidis group C oligosaccharide-CRM197 conjugate vaccine
64. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant
65. A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais
66. Clinical and immunologic responses to human immunodeficiency virus (HIV) type 1SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers
67. A recombinant glycoprotein vaccine for herpes simplex virus type 2: Safety and immunogenicity
68. Safety of 2 recombinant human immunodeficiency virus type 1 (hiv-1) envelope vaccines in neonates born to hiv-1-infected women
69. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120
70. DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques
71. Immunization against the murine malaria parasite Plasmodium yoelii using a recombinant protein with adjuvants developed for clinical use
72. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria
73. A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320
74. Phase I trial in humans of an oil-based adjuvant Seppic Montanide ISA 720
75. Efficacy and safety of new adjuvants
76. Safety and immunogenicity of HIV-1 Tat toxoid in immunocompromised HIV-1-infected patients
77. A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers
78. Safety and immunogenicity of a three-component bloodstage malaria vaccine in adults living in an endemic area of Papua New Guinea
79. Immunologic aspects of liposomes: Presentation and processing of liposomal protein and phospholipid antigens
80. Immunologic adjuvants: A role for liposomes
81. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine
82. Virosomes as an antigen delivery system
83. Archaeosome vaccine adjuvants induce strong humoral, cell-mediated, and memory responses: Comparison to conventional liposomes and alum
84. Immunization of mice with lipopeptide antigens encapsulated in novel liposomes prepared from the polar lipids of various Archaeobacteria elicits rapid and prolonged specific protective immunity against infection with the facultative intracellular pathogen, Listeria monocytogenes
85. Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine
86. Oil-in-water liposomal emulsions: Characterization and potential use in vaccine delivery
87. Targeting immune response induction with cochleate and liposome-based vaccines
88. Polymerized liposomes as potential oral vaccine carriers: Stability and bioavailability
89. ISCOMs and other saponin based adjuvants
90. Induction of protective immunity against influenza virus in a macaque model: Comparison of conventional and iscom vaccines
91. Augmentation of human influenza A virus-specific cytotoxic T lymphocyte memory by influenza vaccine and adjuvanted carriers (ISCOMS)
92. Structure/function studies of QS-21 adjuvant: Assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function
93. Immune-stimulating complexes induce an IL-12-dependent cascade of innate immune responses
94. Influence of antigens and adjuvants on the production of gamma-interferon and antibody by ovine lymphocytes
95. Comparison of immunity generated by nucleic acid-, MF59-, and ISCOM-formulated human immunodeficiency virus type 1 vaccines in Rhesus macaques: Evidence for viral clearance
96. Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine
97. Immune responses to ISCOM((R)) formulations in animal and primate models
98. IscomT adjuvant - A promising adjuvant for influenza virus vaccines
99. The ISCOM™ Technology
100. Lipid vesicle size determines the Th1 or Th2 response to entrapped antigen
101. Lipopeptide particles as the immunologically active component of CTL inducing vaccines
102. Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity
103. Biodegradable microspheres in drug delivery
104. Improving protein therapeutics with sustained-release formulations
105. Biodegradable and biocompatible poly(DL-lactide-co-glycolide) microspheres as an adjuvant for staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies
106. Biodegradable microparticles as controlled release antigen delivery systems
107. Controlled release microparticles for vaccine development
108. Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles
109. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly(lactide-co-glycolide) microparticles
110. Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells
111. Microspheres containing plasmid-encoded antigens elicit cytotoxic T-cell responses
112. Cationic microparticles: A potent delivery system for DNA vaccines
113. The preparation, characterization, and evaluation of cationic microparticles for DNA vaccine delivery
114. Induction of potent immune responses by cationic microparticles with adsorbed HIV DNA vaccines
115. Plasmid DNA adsorbed onto PLG-CTAB microparticles mediates target gene expression and antigen presentation by dendritic cells
116. Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T lymphocytes against recombinant p55 gag from HIV-1
117. Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1
118. Prospects for the development of new and improved vaccines through the use of microencapsulation technology
119. Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines
120. Towards clinical testing of a single-administration tetanus vaccine based on PLA/PLGA microspheres
121. Development of adjuvant-active nonionic block copolymers
122. Poly[di(carboxylatophenoxy)phosphazene] (PCPP) is a potent immunoadjuvant for an influenza vaccine
123. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast
124. Nucleic-acid vaccination primes hepatitis-b virus surface antigen-specific cytotoxic t-lymphocytes in nonresponder mice
125. Virus-like particles as vaccine adjuvants
126. A protein particle vaccine containing multiple malaria epitopes
127. Mucosal or targeted lymph node immunization of macaques with a particulate SIVp27 protein elicits virus-specific CTL in the genito-rectal mucosa and draining lymph nodes
128. Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses
129. Optimism over vaccines administered via mucosal surfaces
130. Enhanced secretory IgA and systemic IgG antibody responses after oral immunization with biodegradable microparticles containing antigen
131. Salivary, gut, vaginal and nasal antibody responses after oral immunization with biodegradable microparticles
132. Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer's patches
133. Microparticles as oral vaccines
134. Immune responses and protection against Bordetella pertussis infection after intranasal immunization of mice with filamentous haemagglutinin in solution or incorporated in biodegradable microparticles
135. Orally administered microencapsulated Bordetella pertussis fimbriae protect mice from B. pertussis respiratory infection
136. Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly(DL-lactide-co-glycolide) microspheres
137. Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles: Effect of formulation and route of immunization on induction of Th1 and Th2 cells
138. Oral immunization with an anti-idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection
139. Protective immunity against Salmonella typhimurium elicited in mice by oral vaccination with phosphorylcholine encapsulated in poly(DL-lactide-co-glycolide) microspheres
140. Protection against vaginal SIV transmission with microencapsulated vaccine
141. Humoral immunity to aerosolized staphylococcal enterotoxin B (SEB), a superantigen, in monkeys vaccinated with SEB toxoid-containing microspheres
142. Intranasal immunization of mice with herpes simplex virus type 2 recombinant gD2: The effect of adjuvants on mucosal and serum antibody responses
143. Poly(DL-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration
144. Biologically erodable microspheres as potential oral drug delivery systems
145. The intestinal uptake of particles and the implications for drug and antigen delivery
146. Tissue distribution of radioactivity following intranasal administration of radioactive microspheres
147. Microparticles and polymers for the mucosal delivery of vaccines
148. Antigen delivery systems: Nonliving microparticles, liposomes, cochleates, and ISCOMS
149. Oral vaccination in man using antigens in particles: Current status
150. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity
151. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltransferase activity act as nontoxic, mucosal adjuvants
152. Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin
153. Induction of antigen-specific antibodies in vaginal secretions by using a non-toxic mutant of heat-labile enterotoxin as a mucosal adjuvant
154. Protease susceptibility and toxicity of heat-labile enterotoxins with a mutation in the active site or in the protease-sensitive loop
155. Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity
156. Protection against Helicobacter pylori infection in mice by intragastric vaccination with H. pylori antigens is achieved using a non-toxic mutant of E. coli heat-labile enterotoxin (LT) as adjuvant
157. Oral administration of influenza vaccine in combination with the adjuvants LT-K63 and LT-R72 induces potent immune responses comparable to or stronger than traditional intramuscular immunization
158. Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants
159. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins
160. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: Differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells
161. Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections
162. Intranasal immunization with recombinant gD2 reduces disease severity and mortality following genital challenge with herpes simplex virus type 2 in guinea pigs
163. MHC class I-restricted cytotoxic lymphocyte responses induced by enterotoxin-based mucosal adjuvants
164. Mutant heat-labile enterotoxins as adjuvants for CTL induction
165. A novel bioadhesive intranasal delivery system for inactivated influenza vaccine
166. Potency of a genetically toxoided mucosal adjuvant derived from the heat-labile enterotoxin of E. coli (LTK63) is not adversely affected by the presence of pre-existing immunity to the adjuvant
167. Phase 1 evaluation of intranasal virosomal influenza vaccine with and without Escherichia coli heat-labile toxin in adult volunteers
168. Safety and immunogenicity of intranasally administered inactivated trivalent virosome-formulated influenza vaccine containing Escherichia coli heat-labile toxin as a mucosal adjuvant
169. Direct effects on antigen-presenting cells and T lymphocytes explain the adjuvanticity of a nontoxic cholera toxin mutant
170. Cholera toxin induces maturation of human dendritic cells and licences them for Th2 priming
171. Skin immunization made possible by cholera toxin
172. Transcutaneous immunization: A human vaccine delivery strategy using a patch
173. Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice
174. The identification of plant lectins with mucosal adjuvant activity
175. Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato
176. Production of hepatitis B surface antigen in transgenic plants for oral immunization
177. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes
178. Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant
179. Cancer-associated MUC1 mucin inhibits human T-cell proliferation, which is reversible by IL-2
180. Therapeutic intragastric vaccination against Helicobacter pylori in mice eradicates an otherwise chronic infection and confers protection against reinfection
181. Oral tolerance: Immune mechanisms and treatment of autoimmune diseases
182. HIV-1-specific cell-mediated immune responses induced by DNA vaccination were enhanced by mannan-coated liposomes and inhibited by anti-interferon-gamma antibody
183. Targeted delivery of antigen to hamster nasal lymphoid tissue with M-cell-directed lectins
184. Lectin-bearing polymerized liposomes as potential oral vaccine carriers
185. Ulex europaeus 1 lectin targets microspheres to mouse Peyer's patch M-cells in vivo
186. Enhanced oral uptake of tomato lectin-conjugated nanoparticles in the rat
187. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit
188. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity
189. The ADP-ribosylating CTA1-DD adjuvant enhances T cell-dependent and independent responses by direct action on B cells involving anti-apoptotic Bcl-2- and germinal center-promoting effects
190. Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein
191. Delivery of exogenous protein antigens to major histocompatibility complex class I pathway in cytosol